These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 16981846)

  • 1. A framework to evaluate the economic impact of pharmacogenomics.
    Stallings SC; Huse D; Finkelstein SN; Crown WH; Witt WP; Maguire J; Hiller AJ; Sinskey AJ; Ginsburg GS
    Pharmacogenomics; 2006 Sep; 7(6):853-62. PubMed ID: 16981846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenomic test that predicts response to inhaled corticosteroids in adults with asthma likely to be cost-saving.
    Wu AC; Gay C; Rett MD; Stout N; Weiss ST; Fuhlbrigge AL
    Pharmacogenomics; 2015; 16(6):591-600. PubMed ID: 25880024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe.
    van den Akker-van Marle ME; Gurwitz D; Detmar SB; Enzing CM; Hopkins MM; Gutierrez de Mesa E; Ibarreta D
    Pharmacogenomics; 2006 Jul; 7(5):783-92. PubMed ID: 16886902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rational prescribing in primary care (RaPP): economic evaluation of an intervention to improve professional practice.
    Fretheim A; Aaserud M; Oxman AD
    PLoS Med; 2006 Jun; 3(6):e216. PubMed ID: 16737349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-utility analysis of the inhaled steroids available in a developing country for the management of pediatric patients with persistent asthma.
    Rodríguez-Martínez CE; Sossa-Briceño MP; Castro-Rodriguez JA
    J Asthma; 2013 May; 50(4):410-8. PubMed ID: 23356720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic opportunities and challenges for pharmacogenomics.
    Deverka PA; Vernon J; McLeod HL
    Annu Rev Pharmacol Toxicol; 2010; 50():423-37. PubMed ID: 20055709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic analysis of asthma practices.
    Stempel DA
    Am J Manag Care; 2000 Oct; 6(17 Suppl):S930-6; discussion S937-9. PubMed ID: 11184564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy].
    Vitale F; Barbieri M; Dirodi B; Vitali Rosati G; Franco E
    Ann Ig; 2013; 25(1):43-56. PubMed ID: 23435779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of cost-effectiveness analysis in the era of pharmacogenomics.
    Flowers CR; Veenstra D
    Pharmacoeconomics; 2004; 22(8):481-93. PubMed ID: 15217305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthma.
    Sullivan SD; Buxton M; Andersson LF; Lamm CJ; Liljas B; Chen YZ; Pauwels RA; Weiss KB
    J Allergy Clin Immunol; 2003 Dec; 112(6):1229-36. PubMed ID: 14657888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine.
    Marra CA; Esdaile JM; Anis AH
    J Rheumatol; 2002 Dec; 29(12):2507-12. PubMed ID: 12465143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of strategies that are intended to prevent kernicterus in newborn infants.
    Suresh GK; Clark RE
    Pediatrics; 2004 Oct; 114(4):917-24. PubMed ID: 15466085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost savings associated with improving appropriate and reducing inappropriate preventive care: cost-consequences analysis.
    Hogg W; Baskerville N; Lemelin J
    BMC Health Serv Res; 2005 Mar; 5(1):20. PubMed ID: 15755330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-minimization analysis of treprostinil vs. epoprostenol as an alternate to oral therapy non-responders for the treatment of pulmonary arterial hypertension.
    Narine L; Hague LK; Walker JH; Vicente C; Schilz R; Desjardins O; Einarson TR; Iskedjian M
    Curr Med Res Opin; 2005 Dec; 21(12):2007-16. PubMed ID: 16368052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the cost-effectiveness of budesonide and sodium cromoglycate in the management of childhood asthma in everyday clinical practice.
    Andersson F; Kjellman M; Forsberg G; Möller C; Arheden L
    Ann Allergy Asthma Immunol; 2001 May; 86(5):537-44. PubMed ID: 11379805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resource utilization in asthma: combined fluticasone propionate/salmeterol compared with inhaled corticosteroids.
    Friedman HS; Yawn BP
    Curr Med Res Opin; 2007 Feb; 23(2):427-34. PubMed ID: 17288696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy.
    Dal Negro RW; Tognella S; Pradelli L
    J Asthma; 2012 Oct; 49(8):843-8. PubMed ID: 22954018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An economic evaluation of budesonide/formoterol for maintenance and reliever treatment in asthma in general practice.
    Goossens LM; Riemersma RA; Postma DS; van der Molen T; Rutten-van Mölken MP
    Adv Ther; 2009 Sep; 26(9):872-85. PubMed ID: 19768640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis in pharmacogenomics.
    Payne K; Shabaruddin FH
    Pharmacogenomics; 2010 May; 11(5):643-6. PubMed ID: 20415553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uncontrolled asthma in a commercially insured population from 2002 to 2007: trends, predictors, and costs.
    Sawicki GS; Vilk Y; Schatz M; Kleinman K; Abrams A; Madden J
    J Asthma; 2010 Jun; 47(5):574-80. PubMed ID: 20560831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.